News Related to Endoscopic Remission

Related coverage linked through entity extraction aliases.

Risankizumab Data in Crohn’s Disease Show Remission, Durable Response and Low Switch Rates

May 05, 2026

Risankizumab data in Crohn’s disease showed 55% clinical remission at week 12 in AFFIRM, durable efficacy through 148 weeks in SEQUENCE, and the lowest 24-month switch rate in a U.S. claims analysis.

TREMFYA® Shows Sustained Remission in Ulcerative Colitis Through Week 140

Feb 21, 2026

Long-term data from the QUASAR extension study show TREMFYA® maintained clinical remission in over 80% of ulcerative colitis patients at Week 140, with more than half achieving endoscopic remission and no new safety concerns observed.